𝔖 Bobbio Scriptorium

✦ LIBER ✦

Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK)

✍ Scribed by Drevs, J.; Mross, K.; Reusch, P.; Peng, B.; Ball, H.; Henry, A.; Laurent, D.; Dugan, M.; Marme, D.; Unger, C.

Book ID: 122726208
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 163 KB
Volume: 35
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(99)81557-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biomarkers (VEGF, BFGF) for assessing th

Biomarkers (VEGF, BFGF) for assessing the biological activity of PTK787/zk222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, in tumours known to overexpress VEGF

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 144 KB

Defining the biologically active dose fo

Defining the biologically active dose for PTK787/ZK222584 (ptk/zk), a vascular endothelial growth factor (VEGF) receptor inhibitor, based on the assessment of two biomarkers [dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), plasma VEGF] in two phase I studies

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Vascular endothelial growth factor recep

Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity

✍ Aisaku YAMAMOTO; Hideaki WATANABE; Hirohiko SUEKI; Takako NAKANISHI; Hajime YASU 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 749 KB

1474 POSTER A phase I, open-label study

1474 POSTER A phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 134 KB

PTK787/ZK 222584, a small molecule tyros

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

✍ Francis J. Giles; Alan F. List; Michael Carroll; Jorge E. Cortes; Joyce Valickas 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 151 KB

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB